Physician profile
Stephanie Stoke
NPI 1285894998
$994.63
in general payments reported to CMS, 2019-2025
12 companies · $715 in 2025
The $715 reported for 2025 was more than what 87% of Occupational Medicine providers received nationally (typical 2025 total: $53.66).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $279 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $358.25 | 2024-2025 | |
| Lilly USA, LLC | $187.60 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Abbvie INC. | $111.23 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $90.10 | 2025 | |
| Novo Nordisk INC | $85.34 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $29.26 | 2024 | Dysport |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.31 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $26.32 | 2025 | Auvelity |
| Acadia Pharmaceuticals INC | $23.07 | 2024 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $21.52 | 2025 | Rexulti |
| Revance Therapeutics, INC. | $18.27 | 2025 | Daxxify |
| Teva Pharmaceuticals USA, INC. | $15.36 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Stoke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.